menu search

DTIL / Precision BioSciences: A Watch List Stock Going Into ASH Presentation

Precision BioSciences: A Watch List Stock Going Into ASH Presentation
Precision BioSciences has been on the candidate list for my Compounding Healthcare “Bio Boom” Portfolio. I am looking to find a spot for DTIL ahead of the ASH presentations. I intend to provide a brief background on Precision BioSciences and will discuss why I believe DTIL deserves a spot in the Bio Boom Portfolio. Read More
Posted: Dec 6 2022, 04:34
Author Name: Seeking Alpha
Views: 103184

DTIL News  

After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)

By Zacks Investment Research
August 18, 2023

After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)

The heavy selling pressure might have exhausted for Precision BioSciences (DTIL) as it is technically in oversold territory now. In addition to this t more_horizontal

Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 4, 2023

Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares t more_horizontal

Precision Biosciences: Plenty Of Positive Updates; Waiting For The Market To Notice

By Seeking Alpha
July 24, 2023

Precision Biosciences: Plenty Of Positive Updates; Waiting For The Market To Notice

Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Unfortunately, the market has yet more_horizontal

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 9, 2023

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares t more_horizontal

Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates

By Zacks Investment Research
March 9, 2023

Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the num more_horizontal

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference

By Business Wire
February 22, 2023

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allog more_horizontal

Precision BioSciences: A Watch List Stock Going Into ASH Presentation

By Seeking Alpha
December 6, 2022

Precision BioSciences: A Watch List Stock Going Into ASH Presentation

Precision BioSciences has been on the candidate list for my Compounding Healthcare “Bio Boom” Portfolio. I am looking to find a spot for DTIL ahea more_horizontal

Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 8, 2022

Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numb more_horizontal


Search within

Pages Search Results: